𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells

✍ Scribed by David S. Adams; Brendan Hasson; Anne Boyer-Boiteau; Adam El-Khishin; Victor E. Shashoua

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
376 KB
Volume
72
Category
Article
ISSN
0360-4012

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Ependymin (EPN) is a goldfish brain neurotrophic factor previously shown to function in a variety of cellular events related to long‐term memory formation and neuronal regeneration. CMX‐8933, an 8‐amino‐acid synthetic peptide fragment of EPN, was designed for aiding an investigation of the biological properties of this glycoprotein. We reported from previous studies that treatment of mouse neuroblastoma (NB2a) cultures with CMX‐8933 promotes activation of transcription factor AP‐1, a characteristic previously associated with the following full‐length neurotrophic factors: nerve growth factor, neurotropin‐3, and brain‐derived neurotrophic factor. The CMX‐8933‐activated AP‐1 specifically bound an AP‐1 consensus probe and appeared to contain c‐Jun and c‐Fos protein components in antibody supershift experiments. Because AP‐1 influences a variety of positive and negative cellular processes, determined in part by its exact protein composition and mechanism of activation, we extended these initial AP‐1 observations in the current study to confirm the identity of the CMX‐8933‐activated c‐Jun and c‐Fos components. CMX‐8933 increases the enzymatic activity of c‐Jun N‐terminal kinase (JNK), increases the phosphorylation of JNK and c‐Jun proteins, and increases the cellular titers of c‐Jun and c‐Fos mRNAs. Furthermore, the AP‐1 activated by CMX‐8933 is functional, insofar as it transactivates both synthetic and natural AP‐1‐dependent reporter plasmids. Inhibition studies indicate that activation of the 8933‐induced AP‐1 occurs via the mitogen‐activated protein kinase pathway. These data are in agreement with the recently proposed model for the conversion of short‐ to long‐term synaptic plasticity and memory, in which a JNK‐activated transcription factor AP‐1, containing c‐Jun and c‐Fos components, functions at the top of a hierarchy of transcription factors known to regulate long‐term neural plasticity. © 2003 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Activation of P2Y2 receptor induces c-FO
Activation of P2Y2 receptor induces c-FOS protein through a pathway involving mitogen-activated protein kinases and phosphoinositide 3-kinases in HeLa cells
✍ Antonella Muscella; Maria Giovanna Elia; Simona Greco; Carlo Storelli; Santo Mar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 1 views

## Abstract The effects of P2Y2 purinoceptor activation on c‐Fos expression and the signaling pathways evoked by extracellular ATP/UTP in HeLa cells were investigated. We found that P2Y2 activation induced c‐Fos protein and phosphorylated the extracellular signal‐regulated kinases 1 and 2 (ERK1/2).

Mutant human tumor suppressor p53 modula
Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-κB, but not c-Jun N-terminal kinase and activated protein-1
✍ Anthony P. Gulati; Yang-Ming Yang; David Harter; Asok Mukhopadhyay; Bharat A. Ag 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 300 KB

## Abstract The roles of the mitogen‐activated kinase protein (MAPK) pathway, nuclear factor‐kappa B (NF‐κB), and activator protein‐1 (AP‐1) in cellular responses to growth factors and mitogen are well established. However, the manner by which these proliferative pathways are affected by the tumor

Gulati AP, Yang Y-M, Harter D, Mukhopadh
Gulati AP, Yang Y-M, Harter D, Mukhopadhyay A, Aggarwal BA, Benzil DL, Whysner J, Albino AP, Murali R, Jhanwar-Uniyal M. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-κB, but not c-Jun N-terminal kinase and activated protein-1. Mol Carcinog 2005;45:26–37.
📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB

## Abstract The original article to which this Erratum refers was published in __Molecular Carcinogenesis__ 2005;45:26–37.